It was a tax cut few saw coming to the tune of $17 billion  on the eve of an election campaign.

Every Australian taxpayer is set to benefit from this announcement in yesterday's federal budget which also recorded a 27.6 billion dollar deficit this financial year followed by a $42.1 billion dollar deficit - with the budget staying in red for the next decade.

Pet owners and their pets are the latest sign of the painful pinch from the cost of living crisis.

Western Australia's RSCPA recently revealed that 30% of surrender requests - or people giving up their pets - is due to cost-of-living pressures... And, sadly, it's a trend that is being spotted nationally. 

The Coalition has thrown its full support behind the salmon industry, but its plans for environment law reform if it wins the election are less clear.

The Queensland government is set to announce its official infrastructure plan for the 2032 Brisbane Olympics this morning.

It's widely expected to back a proposal for a new 60,000 seat venue at Victoria Park.

This will be the third stadium proposal since Brisbane was announced as host back in 2021, with the construction industry concerned it is now facing a race against the clock.

• Guest: Jon Davies, CEO, Australian Constructors Association
• Producer: Brooke Young

Thousands of demonstrators are back on the streets for the sixth consecutive night of protests after the arrest of the President's main political rival Ekrem Imamoglu.

More than 1,100 people have been arrested, including nearly a dozen journalists. 

So would President Erdogan benefit from further charges against Mr Imamoglu, or would they only inflame tensions on the streets?

Men suffering from metastatic prostate cancer in Australia may soon see their treatment options limited if a lawsuit launched by pharmaceutical company Novartis succeeds.

The Swiss company has taken Australia's biggest cancer care provider GenesisCare to the Federal Court. 

The lawsuit alleges the treatment known as Lutetium PSMA I&T infringes on the company's patent for a similar product known as Pluvicto, placing the future use of the revolutionary treatment at risk.

• Guest: Professor Sze Ting Lee, Chair, the  Australasian Association of Nuclear Medicine Specialists Theranostics Committee
• Producer: Grace Stranger

GenesisCare statement: "GenesisCare continues to offer theranostics treatment to patients, including clinical trials and treatment using the TGA approved Lutetium-177 PSMA product, where appropriate. It has, however, suspended prescribing Lutetium-177 PSMA I&T to new patients under the TGA Special Access Scheme. Due to the ongoing nature of legal proceedings, GenesisCare is otherwise unable to comment on the matter."

Novartis statement: "Novartis believes that radioligand therapies, like other medicines and therapeutics, should be evaluated by the TGA for safety and efficacy before being made available to patients through broad national reimbursement.

Moving away from this process, established to ensure the safety and efficacy of medicines provided to Australians, creates a concerning precedent which could impact on future patient access to innovative cancer medicines. 

Pluvicto® (Lutetium (177Lu) vipivotide tetraxetan) is the only registered radioligand therapy (RLT) in Australia reviewed by the TGA for safety and efficacy. 

We recognise the importance of creating a long-term sustainable environment for RLTs in the future. Novartis is committed to working with Government and the healthcare ecosystem to bring our full pipeline of RLTs to Australian patients. "

Health experts around the world are warning that millions of lives could be in jeopardy because of drastic cuts in US aid funding for global HIV and AIDS programs. 

The United Nations says its own UNAIDS agency faces the loss of almost half its budget, which it warns will have knock-on effects for its partner agencies and NGOs around the world.

• Guest: Linda-Gail Bekker, Director, Desmond Tutu HIV Centre
• Producer: Anne Barker 

The prime minister is set to call the election, as soon as this weekend, once tonight's budget is announced and out of the way.

But the question remains: how will tonight's budget lay the path way for the campaign, given the government has already made several key policy announcements with big price tags? 

• Guest: Anthony Albanese, Prime Minister
• Producer: Jacqueline Breen

If you type "anti-wrinkle injections" or "dermal fillers" into a search engine, a cascade of results will pop up, with nearby services being spruiked to you.

But under recently revised guidelines from Australia's Therapeutic Goods Administration, the use of these terms is actually banned.

So why — according to new research from an advocacy group — are there still thousands of websites potentially flouting the rules? 

• Guest:  Professor Robyn Langham, Chief Medical Adviser, Therapeutic Goods Administration (TGA)
• Producer: Lexie Jeuniewic 

The Trump Administration's foreign aid cuts have blown a massive hole in the budgets of global humanitarian organisations and lives are at stake.

But the cuts aren't just coming from the US, with other wealthy countries like Britain, Belgium and The Netherlands are also pulling back on aid funding in real terms.

Now, a new report from the Australian National University's Centre for Development Policy says Australia is spending 10 times more on defence than it is on foreign aid.

• Guest: Retired Admiral Chris Barrie, former Chief of the Defence Force
• Producer: Tim Skelton